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Uterine leiomyomas (fibroids) are the most common benign
tumours in women. They may be single or multiple and their
size varies from a few millimetres to 30 cm or more. By age 50
nearly 70% of white women andmore than 80% of blackwomen
have had at least one fibroid.1Box 1 lists the several risk factors
for fibroids. Symptomatic fibroids are often managed surgically,
and this confers a considerable burden on healthcare costs.2 This
review aims to update non-specialists on the investigation and
management of fibroids. Gaps in current knowledge are
highlighted.
What are fibroids and where are they
found?
Fibroids are a mixture of smooth muscle cells and fibroblasts,
which form hard, round, whorled tumours in the myometrium.
The pathophysiology of fibroids remains unknown, although it
is hypothesised that each fibroid is derived from a mutation in
a single smooth muscle cell.3
The uterus is the commonest site for fibroids (fig 1⇓). The
location may have an effect on symptoms and quality of life.
For example, submucous fibroids may lead to heavy menstrual
bleeding and fertility problems and large fibroids may occupy
two or more locations and can extend from the endometrial
cavity to the serosal surface.
What controls the growth of fibroids?
Oestrogen and progesterone control the proliferation and
maintenance of uterine fibroids, and most medical treatments
act by inhibiting the production of sex steroids or their action.
The primary action of oestrogen is thought to be mediated
through induction of progesterone receptor expression, thereby
allowing leiomyomas to respond to progesterone.9 Hormonal
replacement therapy may cause some growth of fibroids, but
this is of uncertain clinical importance.10
What is the clinical course of uterine
fibroids?
Fibroids are rare in girls before menarche and regress after the
menopause. One retrospective study of 122 premenopausal
women who had at least two transvaginal ultrasound scans over
a median interval of two years reported that fibroids tended to
grow by around 35% of their volume each year, and that small
fibroids (<2 cm) or intramural fibroids grew most quickly,11
although this was variable.
How do women with fibroids present?
Fibroids tend to be asymptomatic. When symptoms do occur,
however, menstrual problems, particularly heavy menstrual
bleeding and pressure symptoms, are typical (box 2)12 and can
have a negative effect on quality of life. They usually require
treatment.13 The size of fibroids does not necessarily determine
symptoms.
When do fibroids need to be investigated?
Fibroids are common, and with the widespread availability of
high resolution ultrasonography, they are often diagnosed
incidentally.
Women presenting in primary care with symptoms suggestive
of fibroids should have their gynaecological history evaluated,
including cervical screening, and should undergo a pelvic
examination for any masses, a haemoglobin estimation to check
for iron deficiency anaemia, and, if urinary symptoms are
present, midstream urine testing to exclude a urinary tract
infection. Diagnostic uncertainty, association with problematic
symptoms, or any clinical or radiological suspicion of
malignancy should prompt referral for further investigations.
Women with asymptomatic fibroids, if the diagnosis is certain,
often do not need further investigation or treatment.
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The bottom line
• Fibroids are commonly asymptomatic and usually do not require treatment once the diagnosis is confirmed by ultrasonography or,
when required, by magnetic resonance imaging
• Women should be made aware of all available treatment options; medical, radiological, and surgical, and why they may or may not
be appropriate
• Medical treatments for heavy menstrual bleeding may be effective in those with fibroids, but there is relatively little evidence to support
this
• Women should also understand that advice on treatment is often based on inadequate evidence, particularly for well established
treatments such as myomectomy
• Hysterectomy is effective, but other conservative surgical and radiological treatments may be preferable and treatment should be
individualised
• Submucosal and possibly intramural fibroids may decrease pregnancy rates; however, evidence to support a role for myomectomy
in enhancing fertility by any route is inconclusive
Sources and selection criteria
The literature search used a combination of MeSH, text words, and appropriate word variants of “fibroids” and “leiomyoma”. We searched
Medline and Embase, Cochrane Reviews, personal references and reference lists in general articles on uterine fibroids. Searching was
limited to publications in English and to studies in women and we have included reference to evidence based guidelines, such as those by
the National Institute of Health and Care Excellence.
Box 1 Risk factors for uterine fibroids
• Race—incidence is higher in black and Asian women than in white women, and multiple fibroids are more common1
• Heredity—risk is higher in women with first degree relatives who have fibroids3
• Age—incidence increases with age during reproductive years4
• Earlier menarche (before age 11)4
• Pregnancy—full term pregnancy is related to lower rates of fibroids5; fibroids are more common in nulliparous women6
• Hormonal contraception—progestin only injectable contraceptives and oral contraceptives reduce the risk of fibroids6 7
• Obesity—weight gain and central distribution of body fat increase the risk of fibroids8
Box 2 Symptoms associated with uterine fibroids
• Heavy menstrual bleeding
• Pelvic pain
• Secondary dysmenorrhoea
• Abdominal distension or distortion
• “Pressure” symptoms—for example, pelvic pressure or discomfort
• Urinary tract problems such as frequency, urgency, urinary incontinence, and hydronephrosis
• Non-specific bowel problems
• Subfertility
The incidence of symptoms depends on the population studied, although a recent systematic review suggests that menstrual
disorder and pelvic pain are the most common symptoms14
When should women be referred to
secondary care?
Women with fibroids that cause symptoms who have not
responded to initial treatments require referral to secondary
care, and some may be suitable for newer uterine conserving
treatments should this be their preference. As fibroids do not
generally cause irregular bleeding, such bleeding should prompt
earlier referral, as should the other symptoms or signs listed in
box 3. Women with subfertility and uterine fibroids should
undergo standard, preliminary investigations as recommended
by the local fertility clinic.
What imaging investigations are useful in
the assessment of fibroids?
If fibroids are suspected, ultrasound scanning is the initial
method of screening that should be performed after an
abdominal and pelvic examination. In most instances it can
determine the size, location, and number of uterine fibroids and
may indicate associations between fibroids and symptoms.15
For example, a fibroid pushing on the bladder may help explain
urinary symptoms. Since the diagnosis of leiomyosarcoma is
based on histology, imaging, including ultrasonography, cannot
be used to diagnose this condition. A systematic review has
shown that delineation of submucous fibroids can be improved
by intracavity saline infusion, with comparable accuracy to
hysteroscopy. If hysteroscopy is required this should be
performed in a dedicated outpatient setting (fig 2⇓). In most
women hysteroscopy usually requires no anaesthesia. However,
transvaginal ultrasonography and diagnostic hysteroscopy should
be considered as complementary investigations and not
alternatives in planning for operative hysteroscopy.16 17
Magnetic resonance imaging is required in some cases to provide
enhanced visualisation of fibroids (box 4 and fig 3⇓). However,
similar to ultrasonography, it cannot diagnose malignancy with
certainty, and current studies are exploring the possibility that
such potential may be increased by new types of imaging.18 19
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Box 3 Red flag symptoms that might suggest other diseases and require referral
• Intermenstrual or postcoital bleeding
• Sudden onset of pain
• Increase in fibroid size in postmenopausal women
Computed tomography is rarely helpful in the management of
uterine fibroids.
When do fibroids need to be treated and
how do doctors and patients select the
best treatment?
Fibroids only require treatment when they cause symptoms.22
Hysterectomy, myomectomy, or uterine artery embolisation
should be considered for fibroids (>3 cm) that cause heavy
menstrual bleeding and affect quality of life.23 The most
important clinical factor in determining any potential treatment
option will be whether fertility or preservation of the uterus, or
both, is desired. This usually steers the options between
observational, medical, radiological, uterine preserving surgery,
and hysterectomy.
Hysterectomy is the definitive method of resolving symptoms
associated with uterine fibroids but is permanently contraceptive
and is considered by many women to be more invasive than
other methods.
What treatments can be considered in
general practice without referral to
specialist care?
Standard medical treatments for heavy menstrual bleeding may
also be effective when such bleeding is associated with fibroids
and may reduce the impact of heavy menstrual bleeding. There
is less evidence supporting these medical treatments in the
presence of uterine fibroids compared with heavy menstrual
bleeding with normal uterine morphology. Table 1⇓ provides
further details.
Which are the most effective medical
treatments?
Medical treatments for fibroids should be targeted against
symptoms. Mefenamic acid and tranexamic acid, which may
reduce heavymenstrual bleeding and pain, are safe and generally
well tolerated. Since they only need to be taken during menses,
major side effects are uncommon.
Hormonal treatments for heavy menstrual bleeding in particular
include the oral contraceptive pill, oral norethisterone, and the
levonorgestrel releasing intrauterine system, although studies
of their efficacy have excluded women with anything other than
small uterine fibroids. Both progesterone and oestrogen can,
however, promote the growth of fibroids.24 25 Selective
progesterone receptor modulators now offer an alternative in
the medical management of fibroids. Several randomised
controlled trials have shown that these agents reduce blood loss
and shrink fibroids.26 27 Ulipristal acetate has recently been
approved for short term use in preparation for surgery (three
months) and long term intermittent use (≥12 months) where
surgery can be avoided.
Gonadotrophin releasing hormone agonists are well established
treatments that can be used in primary care, although usually
initiated in secondary care, to relieve fibroid associated
symptoms, including those related to size. These agonists are
only effective while treatment is ongoing, and symptoms
generally recur on stopping treatment.
What treatments are undertaken in
secondary care?
Radiological treatments
Uterine artery embolisation
Uterine artery embolisation aims to block the blood supply to
the uterus (fig 4⇓). This leads to ischaemic degeneration of
fibroids, although the myometrium obtains a new blood supply
from collateral circulations (ovarian and vaginal). It is an
effective and safe treatment for fibroids.28A recent meta-analysis
of randomised controlled trials measuring patient satisfaction
rates of uterine artery embolisation versus surgery (hysterectomy
or myomectomy) showed that embolisation was equivalent to
surgery at 1-5 years.29 Major complications with uterine artery
embolisation are rare, but minor complications such as nausea,
pain, and vaginal discharge are more common than with surgery,
and reinterventions are more often needed in the embolisation
group within five years. Table 2⇓ summarises this evidence,
considered in the updated Cochrane review of five randomised
controlled trials.29
The impact of uterine artery embolisation on fertility and
pregnancy outcome is not known30 and is the subject of an
ongoing UK multicentre randomised controlled trial.
Surgical treatments
Surgery for uterine fibroids either removes fibroid tissue only
(myomectomy) or removes the uterus and fibroids
(hysterectomy). Both procedures can be performed by
hysteroscopy or laparoscopy, or through abdominal incisions,
although the latter is often preferred for large fibroids. The main
indication for myomectomy rather than hysterectomy is the
preservation of fertility or a desire to avoid hysterectomy. Table
1 summarises the advantages and disadvantages of these
treatments.
Myomectomy
Myomectomy removes fibroids but preserves the uterus.
Although intraoperative bleeding requiring transfusion may
occur in up to 30% of women,31 the chance of emergency
hysterectomy is rare, although the possibility should be part of
the consent process. A recent systematic review discusses
methods tominimise blood loss.32 Systematic reviews of surgical
treatment for uterine fibroids concluded that evidence showing
that myomectomy (either open, laparoscopic, or hysteroscopic)
improves fertility or pregnancy outcomes is inconclusive.33Even
studies of hysteroscopic myomectomy for submucous fibroids
where observational studies have been undertaken to study
changes in fertility, were not of a high quality enough for a
Cochrane review to reach a conclusion.34 35 36 The evidence base
does not support myomectomy, where subfertility is the only
problem.
No robust data comparing fertility sparing options such as
uterine artery embolisation with myomectomy for these
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Box 4 Information available from magnetic resonance imaging and ultrasonography
Pelvic ultrasonography*
Possibly both transabdominal and transvaginal to identify:
• the size and location of fibroids and whether single or multiple
• when fibroids are large, to exclude hydronephrosis
• whether a submucous fibroid is distorting the uterine cavity (improved with addition of saline infusion sonography)16 17
• change in size of single fibroids
Magnetic resonance imaging*
Magnetic resonance imaging is more costly and less easily available than ultrasonography but may be required:
• when the results of ultrasonography are inconclusive
• when more information is needed about the size and location of fibroids since ultrasonography is less able to delineate very large or
multiple fibroids
• before uterine artery embolisation or magnetic resonance guided focused ultrasound, to determine the size and location of fibroids20
• to assess vascularity, which may contribute to predicting the efficacy of uterine artery embolisation, particularly if contrast agents are
used21
*Neither investigation can be used to diagnose malignancy
outcomes exist. Level 1 data show that quality of life outcomes
are equivalent between the two interventions.37
Few studies have prospectively measured the risks associated
with myomectomy and its effect on subsequent pregnancy.
Estimates of major complications are around 2%.38 Regardless
of the route, myomectomy may increase the need for operative
delivery and the risk of uterine rupture.39However, a multicentre
study did not show an increased risk of adverse outcomes for
the fetus after myomectomy.40
Large fibroids are usually removed by open myomectomy. In
some women, however, submucous fibroids (usually <5 cm in
diameter) can be resected hysteroscopically; few studies have
investigated the effect of this on heavy menstrual bleeding,
although some observational studies have noted
improvement.41 42 Thus evidence that hysteroscopic removal of
submucous fibroids improves either the chance of pregnancy
in women with otherwise unexplained subfertility or symptoms
is insufficient to draw conclusions.36
Hysterectomy
Hysterectomy effectively and permanently resolves symptoms
associated with uterine fibroids. Hysterectomy has a mortality
rate of 0.6 to 1.6 per 1000 women. No studies have compared
the incidence of complications between hysterectomy and
myomectomy, although a large observational study found an
increase in complications of hysterectomy with large fibroids.43
What is the relation between fibroids and
fertility?
The exact relation between fibroids and infertility is not well
understood. Some evidence suggests that submucosal fibroids
cause subfertility, although the impact of intramural fibroids is
uncertain. Subserosal fibroids do not seem to be important in
this context. Observational studies support myomectomy for
submucosal fibroids, although a recent Cochrane review was
inconclusive.36 44 45 The effect of intramural fibroids is uncertain
and current consensus does not support their removal to improve
fertility.44 46
What happens to fibroids during
pregnancy?
Data from the United States indicate that around 18% of
African-American women and around 8% of
European-American women have uterine fibroids when scanned
in early pregnancy, although it was not clear when they
developed.47 A systematic review of 23 studies concluded that
while most fibroids are asymptomatic, spontaneous miscarriage
rates were statistically significantly higher in women with
fibroids, although no difference was observed in preterm
delivery rates.48 However, older reproductive age increases the
risk of both fibroids and miscarriage, thus distorting the picture.
Fibroids adjacent to the placenta are more likely to be associated
with bleeding in early pregnancy and spontaneous miscarriage.48
Acute pain in pregnancy (for example, caused by “red
degeneration” (increase in fibroid size outstrips the blood supply,
with resulting ischaemia) or bleeding secondary to fibroids) is
uncommon but should prompt referral for specialist advice.
Treatment of fibroids is only required during pregnancy if acute
complications occur.48
Is there a risk of malignant
transformation?
Leiomyosarcomas are rare malignancies that may be difficult
to distinguish clinically from fibroids. They can only be
diagnosed reliably by histopathology. This is a potential cause
of concern when fibroids are left untreated or managed
conservatively. A recent meta-analysis concluded that
leiomyosarcomas are diagnosed unexpectedly after surgery for
supposed benign fibroids in about 2.94 per 1000 women (95%
confidence interval 1.8 to 4.1), or 1 in 340 women. Risks
increase with age, from fewer than one case per 500 for women
aged less than 30 to 1 in 98 for women aged 75-79.49 The true
prevalence of uterine sarcomas in presumed fibroids is not
known, given the wide range of prevalence.
Fibroids that grow rapidly, particularly after menopause or
despite the use of gonadotrophin releasing hormone agonists
(when fibroids would be expected to decrease in size), often
cause concern and should prompt specialist referral. However,
this clinical picture is not sensitive or specific in discriminating
leiomyosarcomas from benign fibroids, but referral and further
evaluation will determine what further investigations or
treatment, if any, are required.
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Additional educational resources
Resources for healthcare professionals
Lumsden MA. Embolization versus myomectomy versus hysterectomy: which is best, when? Hum Reprod 2000;17:253-9—a review
article
Uterine artery embolisation in the management of uterine fibroids (www.rcog.org.uk/en/guidelines-research-services/guidelines/uterine-
artery-embolisation-in-the-management-of-fibroids/)—clinical recommendations on the use of uterine artery embolisation in themanagement
of fibroids
Resources for patients
NHS Choices. Fibroids (www.nhs.uk/Conditions/Fibroids/Pages/Introduction.aspx)—evidence based advice on uterine fibroids
FEmISA. Fibroid embolisation: information, support, advice (www.femisa.org.uk)—information on fibroid embolisation
British Fibroid Trust. Support (www.britishfibroidtrust.org.uk/)—provides general information
How were patients included in the creation of this article?
Having been a patient with fibroids, Ginette Camps-Walsh critically reviewed this manuscript and provided helpful input. She is now a patient
advocate, campaigning to raise awareness of alternatives to hysterectomy such as uterine artery embolisation.
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Tables
Table 1| Treatment options for fibroids
DisadvantagesAdvantagesStudy detailsTreatment type
Medical treatment:
Efficacy in presence of fibroids is unknownReduced heavy menstrual bleeding in women
without uterine fibroids; improves health related
quality of life
Summary article,w1 randomised
controlled trialw2
Tranexamic
acid/mefenamic acid
Evidence of usefulness in presence of fibroids
is limited; cannot be used if uterine cavity is
distorted by fibroids; high expulsion rate with
submucosal fibroids
Treatment of choice for heavy menstrual bleeding
in absence of fibroids; provides contraception
Retrospective study,w3 prospective
comparative study,w4 prospective
cohort study,w5 NICE National
guideline No 44, 2007
Levonorgestrol
releasing intrauterine
system
Can cause unscheduled bleeding in women with
submucous fibroids; is associated with
endometrial changes that are not yet fully
understood
Reduces heavy menstrual bleeding and shrinks
fibroids; does not cause menopausal side effect or
bone demineralisation; licensed for preoperative use
to shrink fibroids and for intermittent long term use
Randomised controlled trial and open
label study,w6-w8 review article,w9
randomised controlled trial,w10 clinical
reportw11
Selective
progesterone receptor
modulators
Uncertain effect on fibroid volumeCan reduce bleeding and pressure symptoms for
up to six months; reduces heavy menstrual bleeding
and improves fibroid related quality of life
Meta-analysis,w12 Cochrane
systematic revieww13
Mifepristone
Long term therapy beyond six months can
reduce bone density; vasomotor and other
menopausal symptoms are common; more
commonly initiated in secondary care, although
continuation may take place in primary care
Can be used for 3-6 months presurgery to reduce
uterine size, fibroid size, and perioperative blood
loss; leads to amenorrhoea and helps correct iron
deficiency anaemia; menopausal side effects can
be minimised by the use of “add back” hormone
replacement therapy
Literature review,w14 Cochrane
systematic revieww15
Gonadotrophin
releasing hormone
agonists
Radiological and
surgical:
Post-procedure pain can be severe and variable;
alleviation of symptoms can take up to six
months; risk of fibroid expulsion; higher rate of
early re-intervention compared with surgery;
impact on fertility and pregnancy is uncertain
Performed under local anaesthesia (no general
anaesthestic required); requires overnight stay in
hospital; similar success rates and satisfaction rates
to surgery; global uterine fibroid treatment; quick
recovery; decreases fibroid size andmenstrual blood
loss; conserves uterus
Cochrane systematic review,w16
national guideline,w17 randomised
controlled trial,w18 retrospective
study,w19 randomised controlled
trial,w20 review article,w21 literature
review,w22 single centre cohort
Uterine artery
embolisation
analysis,w23 randomised controlled
trial,w24 randomised controlled trialw25
Insufficient evidence regarding role in improving
infertility to conclude that it is best treatment;
associated with major surgical risks; risk of
fibroid regrowth; not a global uterine fibroid
treatment; although morcellation of fibroids is
possible at laparoscopic myomectomy, there
are concerns about this treatmentw30
Conserves uterus; helps resolve bulk symptoms;
can also be performed laparoscopically or
hysteroscopically
Retrospective study,w26 literature
review,w27 Cambridge University
Press,w28 observational studyw29
Myomectomy
Is associated with procedure related morbidity
andmortality, whatever approach is used; higher
surgical complication rates when associated with
large fibroids; not suitable for women wanting
to preserve fertility
Well established effective procedure to permanently
resolve fibroid symptoms; cost effective with high
patient satisfaction rates; vaginal and minimally
invasive laparoscopic approach to this procedure is
suitable in selected cases; global uterine fibroid
treatment and only treatment that prevents
Prospective multicentre study,w31
NA,w32 randomised controlled trial,w33
randomised controlled trialw34
Hysterectomy
recurrence; higher patient satisfaction rates than
with uterine artery embolisation
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Table 2| Summary of evidence on uterine artery embolisation from updated Cochrane review of five randomised controlled trials*
Statistically significantUterine artery embolisationSurgeryOutcomes
YesShorterLongerHospital stay
YesSoonerLaterRecovery of milestones
YesGoodGoodSymptom control
NoImprovedImprovedQuality of life
YesMore commonUncommonReintervention
NoInitially cheaper but decreases with time owing to higher reintervention ratesCost effectiveCost effectiveness
*For discussion see Gupta et al.29
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Figures
Fig 1 Locations of uterine fibroids. Adapted from Mayo Foundation for medical education
(www.mayoclinic.org/diseases-conditions/uterine-fibroids/multimedia/fibroid-locations/img-20006761)
Fig 2 Submucosal fibroid (left) and endometrial polyp (right) visualised on hysteroscopy
Fig 3 Magnetic resonance imaging showing large non-contrast enhancing uterine fibroid after uterine artery embolisation
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Fig 4 (Left) Fluoroscopy before uterine artery embolisation showing uterine arteries and vessels supplying the fibroid. (Right)
Fluoroscopy after uterine artery embolisation showing stasis of uterine arteries. Black arrows indicate uterine arteries, white
arrows indicate area of stasis and embolisation agent
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